| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 101,732 | 119,437 | ||
| Marketable securities | 375,833 | 371,066 | ||
| Restricted cash | 0 | 0 | ||
| Prepaid expenses and other current assets | 5,118 | 5,119 | ||
| Total current assets | 482,683 | 495,622 | ||
| Property and equipment, gross | 1,535 | - | ||
| Less accumulated depreciation | 1,136 | - | ||
| Property and equipment, net | 399 | 462 | ||
| Operating lease right-of-use assets | 475 | 564 | ||
| Deferred offering costs | 217 | - | ||
| Other long-term assets | 7,101 | 7,239 | ||
| Total assets | 490,875 | 503,887 | ||
| Accounts payable | 1,429 | 2,351 | ||
| Accrued expenses and other current liabilities | 13,221 | 12,860 | ||
| Total current liabilities | 14,650 | 15,211 | ||
| Long-term liabilities | 103 | 204 | ||
| Total liabilities | 14,753 | 15,415 | ||
| Common stock, par value 0.001 authorized shares - 100,000,000 issued and outstanding shares - 59,261,286 and 48,936,459 at september 30, 2025 and december 31, 2024, respectively | 59 | 59 | ||
| Additional paid-in capital | 793,341 | 785,941 | ||
| Accumulated other comprehensive income | 221 | -177 | ||
| Accumulated deficit | -317,499 | -297,351 | ||
| Total stockholders' equity | 476,122 | 488,472 | ||
| Total liabilities and stockholders' equity | 490,875 | 503,887 | ||
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)